D. Harris

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

J. Tabernero, T. Yap, D. Olmos, 2012, British Journal of Cancer.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

M. Uttenreuther-Fischer, J. Spicer, S. Rudman, 2015, European journal of cancer.

Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition.

N. Tunariu, M. Germuska, N. deSouza, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of tamoxifen in patients with advanced renal cell carcinoma.

J. Glick, A. Wein, H. Brodovsky, 1980, Cancer treatment reports.

Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

M. Coffey, K. Twigger, V. Roulstone, 2010, Clinical Cancer Research.

Reovirus: Rationale and clinical trial update.

J. D. de Bono, S. Postel-Vinay, R. Lal, 2009, Current opinion in molecular therapeutics.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

M. Uttenreuther-Fischer, A. Suder, J. Ang, 2015, European journal of cancer.

Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

M. Coffey, K. Twigger, V. Roulstone, 2010, Clinical Cancer Research.